The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
News | AHA

September 20, 2021 — The American Heart Association (AHA) announced Sept. 16 it decided to convert from a planned in ...

Home September 20, 2021
Home
Videos | Congenital Heart

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, explains the importance of the heart team ...

Home September 15, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cardiovascular Ultrasound

September 14, 2021 – Us2.ai, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S. Food and ...

Home September 14, 2021
Home
News | Cardiac Rehabilitation

September 14, 2021 – MedAxiom, an American College of Cardiology (ACC) company, released a report detailing cardiac ...

Home September 14, 2021
Home
News | Structural Heart

September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery ...

Home September 13, 2021
Home
News | ECMO Systems

September 13, 2021 — The growing use of mechanical circulatory support (MCS) may contribute to high levels of moral ...

Home September 13, 2021
Home
News | Atrial Fibrillation

September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control ...

Home September 13, 2021
Home
Videos

About 80% of cardiovascular diseases (CVD) are preventable. This is why it is important to identify the people at ...

Home September 13, 2021
Home
News | Sudden Cardiac Arrest

September 13, 2021 — Early coronary angiography in out-of-hospital cardiac arrest (OHCA) patients without ST-segment ...

Home September 13, 2021
Home
An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses.  #ASE #ASE21 #ASE2021 #AI
Feature | Artificial Intelligence | By Dave Fornell, Editor

Artificial intelligence (AI) is growing in all areas of medicine and was the topic of several advanced technology ...

Home September 08, 2021
Home
News | FFR Technologies

September 8, 2021 — Adding systematic fractional flow reserve (FFR) assessment to coronary angiography does not reduce ...

Home September 08, 2021
Home
News | Atrial Fibrillation

September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does ...

Home September 08, 2021
Home
News | Stroke

September 7, 2021 — Carotid artery surgery and stenting have comparable long-term effects on fatal or disabling stroke ...

Home September 07, 2021
Home
Subscribe Now